James C. Kessler

Fundamentals of Fixed Prosthodontics


Скачать книгу

rel="nofollow" href="#fb3_img_img_294623d5-a457-5265-9b53-ef29c95fa075.png" alt="images"/>

      There is no evidence that these diseases are contracted through casual contact with an infected person. However, the nature of dental procedures does produce the risk of contact with blood and tissues. A safe, effective vaccine against HBV is available and is recommended by the Centers for Disease Control47–49 and the ADA Council on Dental Therapeutics50 for all dental personnel who have contact with patients. There is no vaccine against HCV.

      While special precautions should be taken when treating patients with a history of either disease, every patient should be treated as being potentially infectious. Rubber gloves, a surgical mask or full-length plastic face shield, protective eyeglasses (if a shield is not used), and a protective uniform are recommended for the dentist and all other office personnel who will be in contact with the patient during actual treatment (Fig 1-15).

      Concern for these matters does not end at the door to the operatory. Any item contaminated with blood or saliva in the operatory, such as an impression, is just as contaminated when it is touched outside the operatory. The specifics of decontaminating impressions are covered in chapter 17.

      In addition, steps must be taken in a receiving area of the laboratory to isolate and decontaminate items coming from the dental operatory.50 An infection-control program should be established to protect laboratory personnel from infectious diseases, as well as to prevent cross-contamination that could affect a patient when an appliance returns from the laboratory to the operatory for insertion in the patient’s mouth.51 There is more to dental laboratory work than manipulating inert gypsum, wax, resins, metal, and ceramics.

      References

      1. The Glossary of Prosthodontic Terms. J Prosthet Dent 2005;94: 10–92.

      2. American Dental Association. Current Dental Terminology (CDT 2007–2008). Eden Prairie, MN: Ingenix, 2006:47.

      3. Ciancio SC. Medications’ impact on oral health. J Am Dent Assoc 2004;135:1440–1448.

      4. Bent S, Ko R. Commonly used herbal medications in the United States: A review. Am J Med 2004;116:478–485.

      5. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988– 2000. JAMA 2003;290:199–206.

      6. Herman WW, Konzelman JL Jr, Prisant LM; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. New national guidelines on hypertension: A summary for dentistry. J Am Dent Assoc 2004;135:576–584.

      7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–1913 [erratum 2003;361:1060].

      8. Glick M. The new blood pressure guidelines—A digest. J Am Dent Assoc 2004;135:585–586.

      9. Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26(suppl 1):S80–S82.

      10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):Sl–S266.

      11. Rose LF, Mealey B, Minsk L, Cohen DW. Oral care for patients with cardiovascular disease and stroke. J Am Dent Assoc 2002; 133(suppl):37S–44S.

      12. Herman WW, Konzelman JL, Sutley SH. Current perspectives on dental patients receiving coumarin anticoagulant therapy. J Am Dent Assoc 1997;128:327–335.

      13. Jeske AH, Suchko GD; ADA Council on Scientific Affairs and Division of Science, Journal of the American Dental Association. Lack of a scientific basis for routine discontinuation of oral anticoagulant therapy before dental treatment. J Am Dent Assoc 2003;134:1492–1497 [erratum 2004;135:28].

      14. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992;102(4 suppl):312S–326S.

      15. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association. Circulation 1994;89: 1469–1480.

      16. Cannegieter SC, Rosendaal MD, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635–641.

      17. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc 2000;131:77–81.

      18. Scully C, Wolff A. Oral surgery in patients on anticoagulant therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:57–64.

      19. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc 2007;138:739–760.

      20. Tong DC, Rothwell BR. Antibiotic prophylaxis in dentistry: A review and practice recommendations. J Am Dent Assoc 2000; 131:366–374.

      21. Brackett SE. Infective endocarditis and mitral valve prolapse— The unsuspected risk. A case report. Oral Surg Oral Med Oral Pathol 1982;54:273–276.

      22. Miller CS, Egan RM, Falace DA, Rayens MK, Moore CR. Prevalence of infective endocarditis in patients with systemic lupus erythematosis. J Am Dent Assoc 1999;130:387–392.

      23. Lessard E, Glick M, Ahmed S, Saric M. The patient with a heart murmur: Evaluation, assessment and dental considerations. J Am Dent Assoc 2005;136:347–356.

      24. American Dental Association, American Academy of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc 2003;134:895–899.

      25. Glick M. Diabetes: It is all about the numbers [editorial]. J Am Dent Assoc 2006;137:12,14.

      26. Shlossman M, Knowler WC, Pettitt DJ, Genco RJ. Type 2 diabetes mellitus and periodontal disease. J Am Dent Assoc 1990;121:532–536.

      27. Vernillo AT. Dental considerations for the treatment of patients with diabetes mellitus. J Am Dent Assoc 2003;134(special issue): 24S–33S.

      28. American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care 2007;30(suppl 1):S4–S41.

      29. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31:1473–1478 [erratum 2009;32:207].

      30. Kahn R, Fonseca V. Translating the A1C assay. Diabetes Care 2008;31:1704–1707.

      31. Frank RM, Herdly J, Philipe E. Acquired dental defects and salivary gland lesions after irradiation for carcinoma. J Am Dent Assoc 1965;70:868–883.

      32. Bertram U. Xerostomia. Clinical aspects, pathology and pathogenesis. Acta Odontol Scand 1967;25(suppl 49):1–126.

      33. Daniels T, Silverman S, Michalski JP, Greenspan JS, Sylvester RA, Talal N. The oral component of Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol 1975;39:875–885.

      34. Al-Hashimi I. The management of Sjögren’s syndrome in dental practice. J Am Dent Assoc 2001;132:1409–1417.

      35. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouths. Gerodontology 1986;5:75–99.

      36. Guttenberg SA. Bisphosphonates and bone . . . What have we learned?